New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases

Sara Lemoinne, Scott L. Friedman

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations

Abstract

Chronic liver diseases with different etiologies represent a major public health issue worldwide. Liver fibrosis is the common feature of almost all chronic liver diseases and remains a key determinant of clinical prognosis. Over the last two decades, basic science studies have uncovered molecular mechanisms underlying the pathophysiology of chronic liver diseases, leading to the recent development of new anti-fibrotic drugs. These new drugs target different steps in the pathophysiology of chronic liver injury: metabolism of glucose, lipids and bile acids, apoptosis, inflammation and fibrosis. Many targets are shared between non-alcoholic steatohepatitis (NASH) and cholestatic diseases, explaining why some drugs have been assessed concurrently in both conditions. This review reports the most recent clinical trials designed to treat liver fibrosis, with a special focus on NASH and cholestatic diseases.

Original languageEnglish
Pages (from-to)60-70
Number of pages11
JournalCurrent Opinion in Pharmacology
Volume49
DOIs
StatePublished - Dec 2019

Fingerprint

Dive into the research topics of 'New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases'. Together they form a unique fingerprint.

Cite this